Search Results

You are looking at 1 - 10 of 21 items for :

  • "alpha-fetoprotein" x
Clear All
Full access

Tatjana Gavrancic and Yeun-Hee Anna Park

prognosis. It is defined as an alpha fetoprotein (AFP)–producing primary lung carcinoma with pathologic findings of acinar and papillary adenocarcinoma resembling hepatocellular carcinoma (HCC). Globally, only 24 cases have been reported. This report

Full access

Robert J. Motzer, Neeraj Agarwal, Clair Beard, Sam Bhayani, Graeme B. Bolger, Mark K. Buyyounouski, Michael A. Carducci, Sam S. Chang, Toni K. Choueiri, Shilpa Gupta, Steven L. Hancock, Gary R. Hudes, Eric Jonasch, Timothy M. Kuzel, Clayton Lau, Ellis G. Levine, Daniel W. Lin, Kim A. Margolin, M. Dror Michaelson, Thomas Olencki, Roberto Pili, Thomas W. Ratliff, Bruce G. Redman, Cary N. Robertson, Charles J. Ryan, Joel Sheinfeld, Jue Wang and Richard B. Wilder

, such as sarcoma or adenocarcinoma, and is then referred to as a teratoma with malignant transformation. The serum tumor markers alpha-fetoprotein (AFP), lactate dehydrogenase (LDH), and β-human chorionic gonadotropin (β-HCG) are critical in diagnosing

Full access

Nishant Patel, Adam C. Yopp and Amit G. Singal

. Laboratory data of interest included platelet count, creatinine, aspartate aminotransferase, alanine aminotransferase, bilirubin, albumin, international normalized ratio, and alpha fetoprotein (AFP) at presentation and diagnosis. Dates of HCC presentation

Full access

Ju Dong Yang, Michael Luu, Amit G. Singal, Mazen Noureddin, Alexander Kuo, Walid S. Ayoub, Vinay Sundaram, Honore Kotler, Irene K. Kim, Tsuyoshi Todo, Georgios Voidonikolas, Todd V. Brennan, Kambiz Kosari, Andrew S. Klein, Andrew Hendifar, Shelly C. Lu, Nicholas N. Nissen and Jun Gong

data included Charlson-Deyo comorbidity score (0, 1, 2, ≥3), alpha-fetoprotein (AFP) level (normal vs elevated), Model for End-Stage Liver Disease (MELD) score (available since 2010), diagnosis method, treatment, and interval from the date of HCC

Full access

Robert J. Motzer, Neeraj Agarwal, Clair Beard, Graeme B. Bolger, Barry Boston, Michael A. Carducci, Toni K. Choueiri, Robert A. Figlin, Mayer Fishman, Steven L. Hancock, Gary R. Hudes, Eric Jonasch, Anne Kessinger, Timothy M. Kuzel, Paul H. Lange, Ellis G. Levine, Kim A. Margolin, M. Dror Michaelson, Thomas Olencki, Roberto Pili, Bruce G. Redman, Cary N. Robertson, Lawrence H. Schwartz, Joel Sheinfeld and Jue Wang

Testicular Cancer Clinical Practice Guidelines in Oncology NCCN Categories of Evidence and Consensus Category 1: The recommendation is based on high-level evidence (e.g., randomized controlled trials) and there is uniform NCCN consensus. Category 2A: The recommendation is based on lower-level evidence and there is uniform NCCN consensus. Category 2B: The recommendation is based on lower-level evidence and there is nonuniform NCCN consensus (but no major disagreement). Category 3: The recommendation is based on any level of evidence but reflects major disagreement. All recommendations are category 2A unless otherwise noted. Clinical trials: The NCCN believes that the best management for any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged. Overview An estimated 8090 new cases of testicular cancer will be diagnosed in the United States in 2008.1 Germ cell tumors (GCTs) comprise 95% of malignant tumors arising in the testes. These tumors also occur occasionally in extragonadal primary sites, but they are still managed the same as testicular GCTs. Although GCTs are relatively uncommon tumors that comprise only 2% of all human malignancies, they constitute the most common solid tumor in men between the ages of 15 and 34 years. In addition, the worldwide incidence of these tumors has more than doubled in the past 40 years. Several risk factors for GCT development have been identified, including prior history, positive family history, cryptorchidism, testicular dysgenesis, and Klinefelter's syndrome. GCTs are classified as seminoma or nonseminoma. Nonseminomatous tumors often include multiple cell types, including embryonal cell...
Full access

with HBV- or HCV-associated HCC. Determine the change in tumor marker (alpha-fetoprotein) with tivozanib therapy and the effect of tivozanib on several tumor-associated immune response markers Contact: Roswell Park • 877-275-7724 • ASKRPCI

Full access

by Cancer McClure Joan S. MS 4 2015 13 13 4 4 380 380 380 380 0130380 10.6004/jnccn.2015.0053 A Novel Approach Using Sorafenib in Alpha Fetoprotein–Producing Hepatoid Adenocarcinoma of the Lung Gavrancic Tatjana a MD Park Yeun

Full access

Meena A. Prasad and Laura M. Kulik

transplantation . Liver Transpl 2004 ; 10 : 1294 – 1300 . 11. Mailey B Artinyan A Khalili J . Evaluation of absolute serum alpha-fetoprotein levels in liver transplant for hepatocellular cancer . Arch Surg 2011 ; 146 : 26 – 33 . 12

Full access

Laura M. Kulik

to administration of interferon in patients with chronic hepatitis C and a high level of AFP . Dig Dis Sci 2006 ; 51 : 808 – 812 . 42. Di Bisceglie AM Sterling RK Chung RT . HALT-C Trial Group. Serum alpha-fetoprotein levels in patients

Full access

Al B. Benson III, Thomas A. Abrams, Edgar Ben-Josef, P. Mark Bloomston, Jean F. Botha, Bryan M. Clary, Anne Covey, Steven A. Curley, Michael I. D'Angelica, Rene Davila, William D. Ensminger, John F. Gibbs, Daniel Laheru, Mokenge P. Malafa, Jorge Marrero, Steven G. Meranze, Sean J. Mulvihill, James O. Park, James A. Posey, Jasgit Sachdev, Riad Salem, Elin R. Sigurdson, Constantinos Sofocleous, Jean-Nicolas Vauthey, Alan P. Venook, Laura Williams Goff, Yun Yen and Andrew X. Zhu

. Diagnosis and treatment of hepatocellular carcinoma . Gastroenterology 2008 ; 134 : 1752 – 1763 . 30 Zhang B Yang B . Combined alpha fetoprotein testing and ultrasonography as a screening test for primary liver cancer . J Med Screen 1999